Evidence map›Paper›PMID 22815789›Full record

ArticlePloS one2012

Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Minu K Srivastava, Li Zhu, Marni Harris-White, Upendra K Kar, Upendra Kar, Min Huang, Ming F Johnson, Jay M Lee, David Elashoff, Robert Strieter and 2 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 134 papers.

0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

134 citing papers in PubMed, 220 citations in OpenAlex.

  1. Trial
  2. Obesity Promotes Lung Carcinogenesis Through Airway Immune Dysfunction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article

74 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Kar, Upendra [corrected to Kar, Upendra K]
5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Minu K SrivastavaDepartment of Medicine, UCLA Lung Cancer Research Program, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.
Li Zhu
Marni Harris-White
Upendra K Kar
Upendra Kar
Min Huang
Ming F Johnson
Jay M Lee
David Elashoff
Robert Strieter
Steven Dubinett
Sherven Sharma
VA Greater Los Angeles Healthcare System · USUniversity of California, Los Angeles · USUCLA Jonsson Comprehensive Cancer CenterUniversity of Virginia · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA SPORE IN LUNG CANCERP50CA090388 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2001 to 2008
$13.0M
Novel Immune Pathways for Lung Cancer TherapyR01CA126944 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHARMA, SHERVEN · 2008 to 2012
$1.4M
NCATS NIH HHS UL1 TR000124NCI NIH HHS P50 CA090388NCI NIH HHS P50 CA90388NCI NIH HHS R01 CA126944NCI NIH HHS R01 CA95686PHS HHS UL1TR000124
6 · The paper itself

Abstract

backgroundMyeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer. PRINCIPAL

findingsIndividual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls. SIGNIFICANCE: Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion.

Indexed as

Angiogenesis InhibitorsAnimalsAntigen-Presenting CellsAntineoplastic AgentsApoptosisBiomarkers, TumorBone Marrow CellsCarcinoma, Lewis LungCell AdhesionCell ProliferationCytotoxicity, ImmunologicDisease Models, AnimalKiller Cells, NaturalMiceMice, Inbred C57BLMyeloid CellsAngiogenesis InhibitorsAntineoplastic AgentsBiomarkers, TumorOvalbumin

Identifiers

PMID22815789
PMCPMC3398024
OpenAlexW1997297561

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.